Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

Letsinvest2024 Feb. 4 at 5:04 AM

$NTLA what a dog house One day we’ll see $70

0 · Reply

mohdelo13 Feb. 4 at 2:58 AM

$NTLA these sentiments are here are total BS, can’t see a bear post for miles. So dumb ST

0 · Reply

SevenClips Feb. 3 at 11:27 PM

$NTLA easiest hold

0 · Reply

jeojackson Feb. 3 at 8:00 PM

$NTLA Fk. Wish I had more money. 12.5!!!!

1 · Reply

Elamenape2 Feb. 3 at 7:58 PM

$PRME $BEAM $NTLA $CRSP Rare Pediatric Disease PRV Program Reauthorized by Congress! After a two-year campaign to reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program, the rare disease community's relentless advocacy has paid off. https://abcnews.go.com/Politics/house-hold-votes-funding-end-partial-government-shutdown/story?id=129813498

0 · Reply

jeojackson Feb. 3 at 4:54 PM

$NTLA Feb 20 Max Pain is $14. With a lift it will be $24.

1 · Reply

LongT Feb. 3 at 4:54 AM

$NTLA waiting on next hold to be lifted It’s coming. 😁👍🏻

0 · Reply

StockWookie Feb. 3 at 12:37 AM

$NTLA Play it again Sam 400 lottos

0 · Reply

bpeeters Feb. 3 at 12:29 AM

$NTLA this is going to run again.

0 · Reply

free2dream Feb. 2 at 3:55 PM

$SGMO PATIENCE we are going to $3 $XBI $SRPT $NTLA $MYO

0 · Reply

Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder

Jan 27, 2026, 8:13 AM EST - 7 days ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 14, 2026, 2:16 PM EST - 20 days ago

Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 7:30 AM EST - 27 days ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 4:01 PM EST - 2 months ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 26, 2025, 11:34 AM EST - 2 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR CMBM HIMS HTZ LCID REPL SOC

Nov 10, 2025, 3:17 PM EST - 3 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 8, 2025, 5:13 PM EST - 3 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 7, 2025, 5:46 AM EST - 3 months ago

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 5:11 PM EDT - 3 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 27, 2025, 11:17 AM EDT - 3 months ago

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Oct 27, 2025, 7:38 AM EDT - 3 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 24, 2025, 8:15 AM EDT - 3 months ago

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Sep 25, 2025, 1:57 PM EDT - 4 months ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 9:52 AM EDT - 4 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 19, 2025, 2:31 PM EDT - 4 months ago

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Sep 18, 2025, 7:30 AM EDT - 4 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 1, 2025, 8:43 AM EDT - 5 months ago

Why big players are pouring millions in THIS biotech stock

Aug 15, 2025, 12:24 PM EDT - 6 months ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 7, 2025, 8:17 PM EDT - 6 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 7:30 AM EDT - 6 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 30, 2025, 11:07 AM EDT - 6 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

Jul 18, 2025, 8:00 AM EDT - 7 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jun 15, 2025, 10:45 AM EDT - 8 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

May 29, 2025, 11:25 AM EDT - 8 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 20, 2025, 5:47 AM EDT - 9 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

May 18, 2025, 7:25 AM EDT - 9 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 14, 2025, 1:57 PM EDT - 9 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 12, 2025, 9:07 AM EDT - 9 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 8, 2025, 11:37 AM EDT - 9 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:44 AM EDT - 9 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

May 1, 2025, 7:30 AM EDT - 9 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 23, 2025, 9:50 AM EDT - 10 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 10 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 10, 2025, 10:40 AM EDT - 10 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 10 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Letsinvest2024 Feb. 4 at 5:04 AM

$NTLA what a dog house One day we’ll see $70

0 · Reply

mohdelo13 Feb. 4 at 2:58 AM

$NTLA these sentiments are here are total BS, can’t see a bear post for miles. So dumb ST

0 · Reply

SevenClips Feb. 3 at 11:27 PM

$NTLA easiest hold

0 · Reply

jeojackson Feb. 3 at 8:00 PM

$NTLA Fk. Wish I had more money. 12.5!!!!

1 · Reply

Elamenape2 Feb. 3 at 7:58 PM

0 · Reply

jeojackson Feb. 3 at 4:54 PM

$NTLA Feb 20 Max Pain is $14. With a lift it will be $24.

1 · Reply

LongT Feb. 3 at 4:54 AM

$NTLA waiting on next hold to be lifted It’s coming. 😁👍🏻

0 · Reply

StockWookie Feb. 3 at 12:37 AM

$NTLA Play it again Sam 400 lottos

0 · Reply

bpeeters Feb. 3 at 12:29 AM

$NTLA this is going to run again.

0 · Reply

free2dream Feb. 2 at 3:55 PM

$SGMO PATIENCE we are going to $3 $XBI $SRPT $NTLA $MYO

0 · Reply

Rabka505 Feb. 2 at 3:13 PM

$NTLA fall until ER at Feb 26. + the FDA hold

0 · Reply

DoctrBenway Feb. 2 at 3:05 PM

$NTLA Added 6.4% @ 12.9

0 · Reply

free2dream Feb. 2 at 2:48 PM

$XBI nice bounce of the bottom of the channel $CLDX $SRPT $NTLA $SGMO

0 · Reply

APman Feb. 2 at 2:45 PM

$NTLA seriously? 20c delta between bid/ask?

1 · Reply

APman Feb. 2 at 2:37 PM

$NTLA 100k!

0 · Reply

APman Feb. 2 at 2:21 PM

$NTLA Shorts will eventually have to buy back.

0 · Reply

Newcar Feb. 2 at 10:10 AM

$NTLA waiting 10$ to buy more

1 · Reply

UgoGreg Jan. 31 at 4:53 PM

$NTLA https://youtu.be/tAh290QykVA

0 · Reply

3DBuilds Jan. 31 at 5:13 AM

$BEAM $BMY $JNJ $NTLA $REGN

0 · Reply

Picklez_ Jan. 30 at 8:42 PM

$NTLA vanguard wanted a bigger piece

2 · Reply

jeojackson Jan. 30 at 8:23 PM

$NTLA Fk! Is Cathie selling?

2 · Reply

SevenClips Jan. 30 at 8:18 PM

$NTLA keep in mind the hold was only lifted for Magnitude 2; Magnitude trial is still on hold and the hold will be lifted sooner than later, probably next week. Expect another mega pump on that PR but this time those conditioned to sell-the-news will get left behind Still the biggest no brainer buy in the market

2 · Reply

Market Cap	1.52B
Revenue (ttm)	57.88M
Net Income (ttm)	-519.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-896.72%
Debt to Equity Ratio	0.00

Volume	3,616,700
Avg Vol	4,985,996
Day's Range	N/A - N/A
Shares Out	115.83M
Stochastic %K	12%
Beta	2.05
Analysts	Sell
Price Target	$22.85